Table 2

Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure¹

Susan J. Howard, Dasa Cerar, Michael J. Anderson, Ahmed Albarrag, Matthew C. Fisher, Alessandro C. Pasqualotto, Michel Laverdiere, Maiken C. Arendrup, David S. Perlin, and David W. Denning

Author affiliations: Regional Mycology Laboratory, Manchester, UK (S.J. Howard, D.W. Denning); University of Manchester, Manchester Academic Health Science Centre, Manchester (S.J. Howard, M.J. Anderson, A. Albarrag, D.W. Denning); University Medical Centre, Ljubljana, Slovenia (D. Cerar); Imperial College, London, UK (M.C. Fisher); Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (A.C. Pasqualotto); Hôpital Maisonneuve-Rosemont, Montreal, Québec, Canada (M. Laverdiere); Statens Serum Institut, Copenhagen, Denmark (M.C. Ardendrup); Public Health Research Institute, Newark, NJ, USA (D.S. Perlin)

Main Article

Clinical information for 17 patients with azole resistant Aspergillus fumigatus infections*

Patient no.	Age, y/sex	City	No. isolates	Aspergillus disease	Other diseases, y	Daily dose, duration	Serum azole levels, mg/L†	Outcome	Survival
1	50/F	Cambridge, UK	1	CCPA with aspergilloma	Breast cancer, 1990; M. malmoense pulmonary tuberculosis, 1999 and 2005	Vori 200–400 mg, 18 mo	ND	Clinical and radiological failure	Alive
2	21/F	Copenhagen, Denmark	1	ABPA	CF, concomitant bacterial colonization with Staphylococcus aureus and Achromobacter	Itra 200 mg, 14 mo (plus previous courses)	ND	Unknown	Alive
3	40/F	Manchester, UK	2‡	CCPA with aspergilloma, then CFPA	Pulmonary TB with residual bilateral UL scarring and LUL cavity, 1986; smoke inhalation, 1989	Itra 400 mg, 90 mo	15.0–26.0§	Clinical failure	Died
4	72/M	Manchester, UK	3	CCPA with aspergilloma	COPD, squamous cell carcinoma with LUL segmentectomy, 1992	Itra 400 mg, >2 mo	2.9–11.3	No improvement	Died
5	43/M	Montreal, Quebec, Canada	2	Cerebral aspergillosis, Nov 1998	AML-M2, 1997; RUL lobectomy, 1997; AlloHSCT, 1998; GVHD	Itra 400 mg, 4 mo	ND	Regression of cerebral abscess, then IPA with respiratory failure	Died
6	60/M	Manchester, UK	2	CCPA with aspergilloma	COPD, M. szulgai pulmonary infection, 2003; celiac disease	Itra 200–400 mg, 1 mo	<0.8 (200 mg), 5.3–7.7 (400 mg)	Clinical failure	Died
7	77/M	Manchester, UK	1	Acute invasive pulmonary	COPD, possible bronchiectasis	Itra 600–400 mg, 1 mo; vori 400 mg, 12 d	17.0–21.0 (itra)	No improvement; switched to vori, developed toxicity	Died, without IPA
8	46/F	Northampton, UK	2	ABPA	Bronchiectasis, asthma,  AVR, hypermobility syndrome, M. xenopi pulmonary infection, 2007	Itra 200–400 mg, 9 mo	0.0–5.2	Initial improvement, then failure	Alive
9	46/M	Liverpool, UK	12	CCPA with bilateral aspergillomas, CFPA	Pulmonary sarcoidosis, 1988	Itra 200–400 mg, 30 mo	0.9–10.3	Clinical failure	Died
10	41/F	Manchester, UK	2	Aspergillus bronchitis	Bronchiectasis, onychomycosis, 2007; α-1-antitrypsin deficiency	Itra 400 mg pulse, 3 mo	ND	Itra resistance identified, so treated with posa	Alive
11	62/F	Manchester, UK	2	CCPA with aspergilloma	RUL pneumonia, 2002	Itra 400 mg, 1.5 mo	20.0–>25.6	No improvement	Alive
12	29/F	Manchester, UK (Malawi origin)	1	CCPA with 2 aspergillomas	Pulmonary TB, 1995; HIV positive, HAART	Itra 400 mg, 18 mo	2.5–8.4	Improvement then progression	Alive
13	64/M	Preston, UK	4	CCPA with aspergilloma	COPD, bronchiectasis, M. avium pulmonary infection, 2002 and 2006	Itra 600 mg, 10 mo	2.6–4.5	Progression	Alive
14	42/M	Birkenhead, UK	1	CCPA with LUL aspergilloma	Sarcoidosis, COPD, celiac disease; aspergilloma removed as part of left lung transplant, 2007¶	Itra 400 mg, 11 mo	13.8–17.8	Unchanged, switched to vori	Unknown
15	68/F	Wirral, UK	1	Sputum isolate	Cardiac transplant for congestive cardiomyopathy, 1999; chronic cough; 2007; polymyalgia rheumatica, hiatal hernia, oesophagitis	Not documented	NA	Not assessable	Alive
16	12/F	Liverpool, UK	1	Sputum isolate	Unknown	Unknown	Unknown	Unknown	Unknown
17	43/M	Manchester, UK	1	Sputum isolate	Unknown	Unknown	Unknown	Unknown	Unknown

*CCPA , chronic cavitary pulmonary aspergillosis; M., Mycobacterium; vori, voriconazole; ND, not determined; ABPA, allergic bronchopulmonary aspergillosis; CF, cystic fibrosis; itra, itraconazole; CFPA, chronic fibrosing pulmonary aspergillosis; TB, tuberculosis; UL, upper lobe; LUL, left upper lobe; COPD, chronic obstructive pulmonary disease; AML, acute myeloid leukemia; RUL, right upper lobe; AlloHSCT, allogeneic haematopoietic stem cell transplant; GVHD, graft versus host disease; IPA, invasive pulmonary aspergillosis; AVR, aortic valve replacement; posa, posaconazole; HAART, highly active antiretroviral therapy.
†Determined by bioassay (target range 5–15 mg/L).
‡Plus aspergilloma isolates studied, taken at autopsy.
§Received a generic formulation of itra, resulting in lower concentrations (i.e., 4.6 mg/L) and then probably was noncompliant at end of treatment period.
¶Successfully completed with vori treatment.

Main Article

¹These data were presented in part at the 2nd Advances Against Aspergillosis meeting, February 22–26, 2006, Athens, Greece; and 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, 2006, San Francisco, CA, USA.

Page created: November 09, 2010

Page updated: November 09, 2010

Page reviewed: November 09, 2010

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

Volume 15, Number 7—July 2009

Research

Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure1

Table 2

Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure¹